retatrutide approval timeline The Dosage Chart How To Get Retatrutide with
Description
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
These early non-responders often exit programs within the first few weeks, citing failure to achieve the expected goal and expressing feelings of frustration and disappointment
No referral is needed for most services
Pregnancy and breastfeeding also require stopping these medications
